Masters, Integrated Masters in Natural or Agricultural or Pharmaceutical Sciences, MVSc, Animal Sciences. OR Bachelors degree in Engineering or Technology or Medicine from a recognized University.
First Class Post-Graduate Degree in Life Sciences Microbiology, Biotechnology, Biochemistry etc. Candidates with prior experience in molecular biology techniques including gene cloning and protein purification will be preferred.
Candidates having B.Sc. or an equivalent qualification in Life Sciences or allied subjects such as Biotechnology, Microbiology, Biochemistry with a minimum of 55% marks.
Masters degree in a relevant field of Life Sciences, Clinical research, Nursing. experience in Clinical trial Pharma sponsored, Investigator initiated or Research funded project.
Post-Graduate M.Sc. in Biochemistry, Biotechnology, Microbiology, Life sciences.1-6 years of hands-on experience in relevant field, preferred Vaccine, Biotech background.
Looking for candidates with relevant experience in OSD regulated plant. RMG, FBE,FETTE, Auto coaters, Bottle Packing line with track and trace systems.
As reported by Reuters, U.S. pharmaceutical giant Eli Lilly has launched its Mounjaro KwikPen in India, expanding its portfolio of treatments for diabetes and obesity.
Lupin Limited, a leading global pharmaceutical company, has announced the launch of its Prucalopride Tablets in 1 mg and 2 mg strengths in the United States, following the recent approval of its Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (FDA).
In a promising development for transplant medicine, global healthcare leader Sanofi has announced that its investigational therapy riliprubart has received Orphan Drug Designation from the U.S. Food and Drug Administration.
A pioneering gene therapy engineered by researchers at the University of California San Diego (UCSD) School of Medicine demonstrates remarkable promise in halting, and potentially reversing, cognitive decline in preclinical Alzheimer’s models.
Glenmark Pharmaceuticals Ltd., a research-driven global pharmaceutical company, has announced the launch of TEVIMBRA® (tislelizumab) in India, marking its official entry into the immuno-oncology segment.
Chronic pain is a debilitating condition that severely impacts quality of life, often leading to reliance on opioid medications with their severe side effects and addiction risks.